indicated that activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) relies on MYD88, with the MYD88 L265P mutation being particularly prevalent in systemic DLBCL (61). This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.